Brand Names for Metformin and Dapagliflozin Combination
The fixed-dose combination of metformin and dapagliflozin is marketed under the brand name Xigduo (or Xigduo XR for the extended-release formulation). 1, 2
Available Formulations
Xigduo XR is the primary brand name used in the United States and many other markets for the fixed-dose combination containing dapagliflozin and metformin extended-release 3, 2
The combination is administered orally once daily, which enhances medication adherence compared to taking separate tablets 3
Clinical Context
This fixed-dose combination addresses two complementary pathophysiological mechanisms: metformin reduces insulin resistance and hepatic glucose production, while dapagliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption 1, 4
The combination provides superior glycemic control compared to either agent alone, with HbA1c reductions of approximately 2% in treatment-naïve patients with baseline HbA1c of 7.5-12% 5
Additional benefits include weight loss of 2-3 kg and modest systolic blood pressure reduction of 3-5 mmHg 3
Important Prescribing Considerations
Dapagliflozin can be initiated at 10 mg daily if eGFR ≥25 mL/min/1.73m², but should not be initiated if eGFR <25 mL/min/1.73m² 6
The combination carries a low risk of hypoglycemia when used without insulin or sulfonylureas 3
Patients should be counseled on daily genital hygiene to reduce the risk of genital mycotic infections, which occur in approximately 6-13% of patients treated with dapagliflozin 5, 6